Overview

A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A
Phase:
Phase 3
Details
Lead Sponsor:
Addpharma Inc.
Treatments:
Atorvastatin
Ezetimibe